See Also

Medical product maker AtCor Medical says it has signed its fourth supply contract in the US since healthcare reform legislation was passed.

AtCor says it has signed a $US800,000 ($806,858) contract to supply its central blood pressure monitoring system, SphygmoCor, and clinical trial support services to an international pharmaceuticals company.

"This transaction further demonstrates the rebounding activity in the pharmaceutical trial sector and confirms AtCor's market position as the leading provider of non-invasive central blood pressure and arterial-stiffness measurement in clinical trials," chief executive Duncan Ross said.

By 1400 AEDT, AtCor shares had added 2.5 cents, or 26.32 per cent, to 12 cents.